Navigation Links
Adventrx To Develop ANX-188 For Complications Of Arterial Disease
Date:2/28/2013

al hold"; the risk of suspension or termination of a clinical study, including due to lack of adequate funding or patient safety concerns; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of planned phase 2 clinical studies of ANX-188 in any particular indication in which ADVENTRX determines to develop ANX-188, including ALI, which likely would increase the total time and cost of development in the indication; the risk that clinical studies of ANX-188 are not successfully executed and/or do not successfully demonstrate its safety or efficacy; the risk that, even if clinical studies are successful, the FDA determines they are not sufficient to support a new drug application; the risk that even if clinical studies of ANX-188 in one indication are successful, clinical studies in another indication may not be successful; ADVENTRX's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of ANX-188, including clinical studies, and regulatory activities for ANX-188 and that such third parties may fail to perform as expected; ADVENTRX's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for ADVENTRX to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner ANX-188 at inopportune times or pursue less expensive but higher-risk development paths if it is unable to raise sufficient additional capital as needed; the risk that acceptable partnering opportunities for ANX-188 may not be available in particular jurisdictions or indications and, consequently, ADVENTRX may not be able to pursue development of ANX-188 in certain jurisdictions and indications; the risk that the FDA does not grant marketing approval of ANX-188, on a timely basis,
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications
2. ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4
3. ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12
4. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
5. ADVENTRX Reports Third Quarter 2012 Financial Results
6. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
7. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
8. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
9. ADVENTRX Announces Appointment Of Chief Medical Officer
10. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
11. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015 Fair Rate Funding, ... Jersey , reports a dramatic increase in lawsuit filings ... of filed Xarelto lawsuits in the Philadelphia ... to over 300 cases.  In the Louisiana ... for the Eastern District of Louisiana , ...
(Date:9/4/2015)... 2015  Pharmaceutical companies today rely heavily on ... Specialists (FBMS) to build and strengthen vital relationships ... in critical therapeutic areas. To ... are expanding the critical MSL function into global ... objectives and to achieve regional consistency, compliance, and ...
(Date:9/4/2015)... , Sept. 4, 2015  Dohmen Company CEO ... the Metropolitan Milwaukee Association of Commerce,s annual ,Future 50, ... the Pfister Hotel. The ,Future 50, Awards highlights the ... and young firms headquartered in the seven-county ... called Milwaukee home for more ...
Breaking Medicine Technology:Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2Dohmen CEO Cynthia LaConte to Keynote MMAC 'Future 50' Awards Luncheon 2
... ... 7 , Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ) and ... of positive data from a phase 1 study of TRU-016 in ... 2009 American Society of Hematology (ASH) Annual Meeting. TRU-016 is a ...
... , HOBOKEN, N.J., Dec. 7 ... the U.S. Food and Drug Administration has approved ... in patients with all types of von Willebrand disease (VWD). Wilate® ... Factor VIII Concentrate (Human) that demonstrated efficacy for all types of ...
Cached Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5
(Date:9/4/2015)... ... September 04, 2015 , ... ... communities, is launching a charity effort to provide for the family of Grace, ... an enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction – the inability ...
(Date:9/4/2015)... ... 2015 , ... Inmar announced today that its regulatory experts ... Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , With the complex ... industry, it can be difficult for companies to navigate, stay abreast of all ...
(Date:9/4/2015)... Texas (PRWEB) , ... September 04, 2015 , ... ... recipient of three separate “Partner of the Year” awards at this year’s Microsoft ... being named Microsoft’s 2015 “Partner of the Year” Award Winner for Data Platform ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... technology is now available at CitiDent. CEREC is a newer method for creating ... saving time for patients by eliminating the need for multiple appointments, CEREC produces ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former Navy SEAL who ... the Ironman World Championships in Kona on October 10th. , Mike is running the ... (TBI) through combat and the cutting-edge treatments that restore their quality of life. ...
Breaking Medicine News(10 mins):Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2
... included nearly 57,000 women who had been followed for ... -- Hormone therapy may lower a woman,s risk of ... the hormones. , This new finding, published in the ... , further complicates an already murky picture of the ...
... SANTA CLARA, Calif., January 8 Align Technology,Inc. (Nasdaq: ... today that the,Company will report fourth quarter and fiscal ... the close of market. Financial results will,be released over ... on the,Investor Relations section of the Company,s website at, ...
... Calif., Jan. 8 TEAC America, Inc. launches its,next ... dye-sublimation disc printer available, during the CES Show at,the ... The P-55C printer can be integrated ... Discathlon 2. With TEAC,s,AL220S and AL550S, customers can ...
... Vyvanse as the Clinical Gold Standard, According to ... 8 Decision Resources, one of the world,s ... and healthcare issues, finds that physicians indicate there ... effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today ... officer. Formerly president and chief operating officer,Popovits is ... In addition, G.,Bradley Cole has been appointed as chief ... chief financial officer, reporting to Popovits. , ...
... and FirstDoc (Documentum) Solutions Deliver Regulatory Document Management ... CSC (NYSE: CSC ) announced today ... content management (ECM) solutions, adding features designed to ... the document life cycle and the growing collaboration ...
Cached Medicine News:Health News:Hormone Therapy May Cut Colorectal Cancer Risk 2Health News:Align Technology to Announce Fourth Quarter and Fiscal Year 2008 Results on January 28, 2009 2Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 3Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 2Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 3
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
Conversion Kits For Modular Incubator Chamber...
Medicine Products: